Phosphodiesterase inhibitors and the cardiovascular system
نویسندگان
چکیده
منابع مشابه
[5-phosphodiesterase inhibitors and cardiovascular risk].
important predictors of erectile dysfunction. Am J Epidemiol 1994;140:930—7. [7] Roumeguère Th, Wespes E, Carpentier Y, Hoffmann P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003;44:355—9. [8] Ponholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is erectile dysfunction an indicator for increased ...
متن کاملEmerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Phosphodiesterase type-5 (PDE-5) is an enzyme that catalyzes the hydrolytic degradation of cyclic GMP - an essential intracellular second messenger that modulates diverse biological processes in living cells. Three selective inhibitors of PDE-5 - sildenafil, vardenafil and tadalafil - have been successfully used by millions of men worldwide for the treatment of erectile dysfunction. Also, silde...
متن کاملTheophylline and phosphodiesterase inhibitors.
Correspondence: *Inserm U408, Unité de Pneumologie de l'Hôpital Bichat, Paris, France. ** and Dept of Thoracic Medicine, National Heart and Lung Institute, London, UK. This issue of the European Respiratory Journal starts a series of short reviews based on a Satellite Meeting held during the European Respiratory Society Annual Meeting in Nice in October 1994. The symposium was supported by Byk ...
متن کاملPulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors.
OBJECTIVE To compare the direct pulmonary vasodilating activity and specificity of phosphodiesterase-5 (zaprinast) and phosphodiesterase-3 (milrinone) inhibitors on the pulmonary vascular (PV) bed of the spontaneously breathing cat with an intact chest. DESIGN Prospective, randomized animal study. SETTING Laboratory of university hospital. SUBJECTS Experiments were performed in vivo in in...
متن کاملCardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Within the last year, 2 new phosphodiesterase-5 (PDE5) inhibitors have been approved by the US Food and Drug Administration (FDA) for the treatment of erectile dysfunction (ED). Currently, sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) are on the market. These agents have been shown to be effective in a broad population of men with ED, including patients with vascular disease...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Continuing Education in Anaesthesia Critical Care & Pain
سال: 2007
ISSN: 1743-1816
DOI: 10.1093/bjaceaccp/mkm039